ArticleScientific reports2026
Protein microarray-based profiling of salivary IgA antibodies against human proteins in COVID-19 patients with depressive symptoms.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood protein biomarkers for rheumatoid arthritis patients complicated by interstitial lung disease.Frontiers in medicine · 2026Article
- Serum protein biomarkers for polymyalgia rheumatica: a case-control study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To understand the pathophysiology and etiology of COVID-19 patients with depressive symptoms, we investigated the presence of autoantibodies associated with neurological sequelae using salivary IgA antibody profiling in COVID-19 patients with depressive symptoms. We used a human protein microarray system to comprehensively measure IgA antibodies against human proteins in the saliva of three groups of participants: those who developed moderate or severe depressive symptoms 2–14 months after SARS-CoV-2 infection (the ‘COVID-19 group’), those with no infection history who showed no depressive symptoms or only mild depressive symptoms (the ‘healthy control group’), and those with no infection history who were diagnosed with depression. As a result, 65 types of IgA antibodies recognizing human proteins were identified, all of which were present only in the COVID-19 group and not in the healthy control group. Several antigens recognized by these antibodies are associated with depressive symptoms. These findings suggest that distinctive salivary IgA antibody profiles may be associated with depressive symptoms following SARS-CoV-2 infection and could serve as candidate biomarkers for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.